Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 17/20 | 0.81 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL313511 | 0.99 | CCR2 (0.79) | CCR2RAB9AGAAHTTCCR5 | |
| Iodide SCHEMBL3075475 | 0.99 | CCR2 (0.79) | CCR2RAB9AGAAHTTCCR5 | |
| SCHEMBL13148149 | 0.89 | CCR2 (1.00) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL2906546 | 0.89 | CCR2 (0.98) | CCR2CCR5 | |
| SCHEMBL2697394 | 0.87 | CCR2 (0.62) | CCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL13148270 | 0.86 | CCR2 (0.68) | CCR2CCR5 | |
| Iodide SCHEMBL5179621 | 0.86 | CCR2 (0.61) | CCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL314961 | 0.86 | CCR2 (0.61) | CCR2RAB9ANPC1SMN1; SMN2MEN1 | |
| Iodide SCHEMBL17555087 | 0.85 | CCR2 (0.67) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL313758 | 0.85 | CCR2 (0.67) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093428-B2 | Synthesis of quaternary salt compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-10 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | CCR2, CCR1, CCL11 | CCR2 1/4885RAB9A 3203/4885GAA 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.